The Spectrum registry, the world’s largest, single device ophthalmology registry to evaluate the efficacy and safety of Ivantis’ Hydrus Microstent for the treatment of mild to moderate primary open-angle glaucoma (POAG), has completed enrolment.
Due to be released in full in 2021, the registry includes almost 3,000 eyes, including 700 surgeries in which the Hydrus Microstent was implanted in a stand-alone glaucoma procedure. According to Ivantis, a cohort of nearly 250 eyes followed up during the three years, showed a reduction in intraocular pressure of 29%, with a commensurate reduction of one medication compared to preoperative levels.
Professor Gus Gazzard, Moorfield’s glaucoma service director in the UK, is leading the European contribution with more than 200 cases. "I have been using the Hydrus stent for nearly five years across a vast array of patients, ranging from my patients with mild disease undergoing cataract surgery to those who have highly advanced glaucoma. I find the Hydrus to be uniquely versatile in terms of providing the best combination of safety and efficacy for a remarkably broad range of patients. I have been particularly impressed by the sustained efficacy the device provides in a very safe manner, even in the absence of cataract surgery, and I am excited to see what a comprehensive review of this extraordinary data set will provide in terms of our arsenal of MIGS knowledge."
Roughly the size of an eyelash, the Hydrus Microstent is a next-generation MIGS device designed to reduce eye pressure by re-establishing flow through Schlemm's canal. Placed into the trabecular meshwork, it restores the flow of fluid in the eye using a trimodal mechanism of action, said Ivantis. First, it creates a bypass through the trabecular meshwork, allowing outflow of aqueous humor. Secondly, it dilates and scaffolds the canal to augment outflow and finally, spanning 90 degrees of the canal, it provides consistent access to the fluid collector channels in the eye.
